- Conditions
- Acute Myeloid Leukemia
- Interventions
- Fludarabine, Melphalan, Pembrolizumab
- Drug
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 725
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab
- Biological · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Pembrolizumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
- Interventions
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Drug
- Lead sponsor
- Dan Zandberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- K27M peptide, Nivolumab
- Biological · Drug
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 14
- States / cities
- San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Nivolumab, Cisplatin, Cetuximab, IMRT
- Drug · Radiation
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
- Drug
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Orange, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Malignant Melanoma
- Interventions
- Atezolizumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Detroit, Michigan + 3 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Nemvaleukin Alfa, Pembrolizumab
- Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
- Conditions
- Melanoma (Skin), Skin Cancer
- Interventions
- Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2
- Drug · Procedure · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Etigilimab, Nivolumab
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Greenbrae, California • Los Angeles, California + 11 more
- Conditions
- Glioblastoma
- Interventions
- Zimberelimab, Domvanalimab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- San Francisco, California • New Haven, Connecticut • Boston, Massachusetts
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- The Woodlands, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more
- Conditions
- Advanced Solid Tumors
- Interventions
- obrindatamab, retifanlimab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 6 more
- Conditions
- Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
- Interventions
- Lerapolturev, 5% DDM
- Biological · Other
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Myrtle Beach, South Carolina
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
- Interventions
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Other · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
- Interventions
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Memgen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Durham, North Carolina
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 60 more
- Conditions
- Solid Tumors
- Interventions
- BMS-986156, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 4 more
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide, Rescue Medications
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more
- Conditions
- Hepatocellular Carcinoma (HCC), Solid Malignancies
- Interventions
- FGF401, PDR001
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Bladder Cancer
- Interventions
- Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- Lawrence Fong
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California